[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579784":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":64,"collaborators":22,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":22,"eligibilityCriteria":71,"healthyVolunteers":68,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":22,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":22,"overallStatus":49,"whyStopped":22,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Northside Hospital, Inc.","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tacrolimus + MMF + Post-Transplant Cyclophosphamide","EXPERIMENTAL","Cyclophosphamide 50mg\u002Fkg\u002Fd Days +3 and +4 after transplant Tacrolimus Day -1 to Day +90 or Day +180 after transplant MMF 15mg\u002Fkg PO TID Day 0 to Day +35",[13,14,15],"Drug: Tacrolimus","Drug: Cyclophosphamide","Drug: Mycofenolate mofetil",[17,23,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Tacrolimus","Begins Day -1 and continues to Day +90 or Day +180 after transplant",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"Cyclophosphamide","Given Days +3 and +4 after transplant",[9],{"type":18,"name":28,"description":29,"armGroupLabels":30,"otherNames":22},"Mycofenolate mofetil","Given Day 0 to Day +35 after transplant",[9],[32],{"name":33,"affiliation":34,"role":35},"Melhem Solh, MD","The Blood and Marrow Transplant Group of Georgia","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":22,"email":41},"Melh Solh, MD","CONTACT","404-255-1930","msolh@bmtga.com",{"name":43,"role":39,"phone":44,"phoneExt":22,"email":45},"Caitlin Guzowski, MBA, MHA, CCRC","404-851-8523","caitlin.guzowski@northside.com",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Northside Hospital","RECRUITING","Atlanta","Georgia","30342","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-84.38798,33.749,{"lat":59,"lon":58},[62,63],{"name":43,"role":39,"phone":44,"phoneExt":22,"email":45},{"name":33,"role":35,"phone":22,"phoneExt":22,"email":22},{"type":65,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100579784","phase-2-early-use-of-tacrolimus-in-hla-mismatched-haploidentical-allogeneic-hematopoietic-transplantation-with-post-transplant-cyclophosphamide-100579784",false,"NCT06828796","Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide","Inclusion Criteria:\n\n* Availability of a 5\u002F10-8\u002F10 mismatched (HLA-A, B, DR) haploidentical related donor with a negative HLA cross-match in the host vs. graft direction and willing to provide peripheral blood stem cells\n* Karnofsky status \\>\u002F= 70%\n* Hematologic malignancy requiring allogeneic transplantation\n* First allogeneic transplant only. Prior autologous transplant is allowed.\n\nExclusion Criteria:\n\n* Poor cardiac function: LVEF \\\u003C40%\n* Poor pulmonary function: FEV1 and FVC \\\u003C50% predicted\n* Poor liver function: bilirubin \\>\u002F= 3mg\u002FdL (not due to hemolysis, Gilbert's or primary malignancy)\n* Poor renal function: Creatinine \\>\u002F= 2mg\u002FdL or creatinine clearance (calculated or measured creatinine clearance is permitted) \\\u003C40mL\u002Fmin based on Traditional Cockcroft-Gault formula\n* Women of childbearing potential who currently are pregnant or who are not practicing adequate contraception\n* Patients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow up","ALL","18 Years","80 Years",{"count":76,"type":77},20,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process",[83,84],"Hematologic Disease and Disorders","Hematopoietic Cell Transplant","2026-04-15",{"date":87,"type":88},"2026-04-16","ACTUAL",{"date":90,"type":88},"2025-07-03",{"date":92,"type":77},"2028-06-30",{"name":5,"class":6},1]